相关实验视频
Updated: Jun 18, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
抗IL23/12药物和JAK抑制剂用于炎症性肠病
Zhezhe Tian1,2,3, Qiaorui Zhao1,3,4, Xiu Teng1,3,4
1Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
Frontiers in immunology
|August 1, 2024
概括
炎症性肠病 (IBD) 治疗正在推进,新的生物和小分子药物向IL-12和IL-23通路. 这些疗法在治疗IBD方面有望提高疗效和安全性,可能导致疾病缓解.
科学领域:
- 胃肠道学和免疫学
- 慢性炎症疾病 慢性炎症疾病
- 药物开发 药物开发
背景情况:
- 炎症性肠病 (IBD) 是一种慢性胃肠道疾病,其全球发病率正在上升.
- IBD的确切原因尚不清楚,但遗传,环境和免疫因素都与此有关.
- 介质素-12 (IL-12) 和介质素-23 (IL-23) 信号通路被认为是IBD病原体的贡献者.
研究的目的:
- 审查IBD治疗方面的进展.
- 突出针对IL-12和IL-23通路的新疗法的作用.
- 讨论实现IBD缓解的未来治疗环境.
主要方法:
- 关于IBD病原和治疗的当前文献的综述.
- 对针对IL-12/IL-23的生物药物和小分子药物的临床试验数据的分析.
- 评估已批准和新兴的IBD治疗策略.
主要成果:
- 用生物药物和小分子药物实现了IBD治疗的显著改善.
- 针对IL-12和IL-23的新疗法在临床试验中已经证明了积极的疗效和安全性.
- 一些针对IBD的向疗法已获得监管部门的批准.
结论:
- 向治疗,特别是抑制IL-12和IL-23的向治疗,在IBD管理方面取得了重大进展.
- 早期和积极的治疗对于减轻IBD并发症和减少医疗保健利用至关重要.
- 未来的研究有望开发炎症性肠道疾病的治愈疗法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Drugs for Treatment of Ulcerative Colitis in IBD
133
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
133
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K

